ALMRAlamar Biosciences, Inc.
Price
End-of-day closes, not the intraday tick.
The five questions
2 of 5 availableOnly two of the five can be answered for ALMR today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
Charts
As reported to the SEC, without any scoring.
Business segments
Q2 2026 · $29.4MThe company’s own SEC segment disclosure.
- Consumables$15.5M53%
- Instruments$7.8M26%
- Service$6.2M21%
Alamar Biosciences, Inc. (ALMR) reported revenue of $29M in Q2 2026 (quarter ended Jun 30, 2026), up 125% from the same quarter a year earlier. That came with a gross margin of 60% and net loss of $13M. Its largest product in Q2 2026 was Consumables at $15M, 53% of the disclosed total, well ahead of Instruments at 26%. The next results filing is expected around Nov 9, 2026, a quarter after the last one.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 1, 2026On August 28, 2026, the board of directors (the “Board”) of Alamar Biosciences, Inc. (the “Company”) appointed Robert Ragusa to the Board, effective as of September 1, 2026.Director or officer change · Form 8-K
- Aug 10, 2026Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance.Earnings release · press release
- Jul 15, 2026Alamar Biosciences, Inc. (the “Company”) is deeply saddened to report that Ian Ratcliffe, a member of the Company’s board of directors (the “Board”), passed away on July 5, 2026.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Medical Devices
The closest names by size in the same industry